The Evolution of AREDS

Although AREDS2 remains the evidence-based standard for AMD supplementation, new research is reshaping discussion around future AMD formulations.

By: Maya Patel, MS, BA,, Zack Oakey, MD

Retinal Physician June 1, 2026

5 Key Takeaways

1

AREDS2 is the current standard for AMD supplementation, offering a modest reduction in disease progression risk.
2

The understanding of AMD has evolved to recognize it as a multifactorial disease involving inflammation and mitochondrial dysfunction.
3

AREDS2 replaced beta-carotene with lutein and zeaxanthin, improving safety while maintaining protective effects against AMD.
4

Current AMD formulations do not address key pathways like chronic inflammation and complement dysregulation, highlighting limitations.
5

Future AMD strategies may require personalized approaches, moving beyond the one-size-fits-all model of current supplementation.

Maya Patel

Specialties: Ophthalmology

Bio: Maya Patel, MS, BA, is a researcher specializing in ophthalmology with a focus on age-related macular degeneration (AMD). She has contributed to advancing understanding of AMD pathophysiology, particularly regarding the evolution of supplementation strategies such as AREDS formulations. Her work explores the multifactorial nature of AMD, including oxidative stress, inflammation, complement dysregulation, mitochondrial dysfunction, and lipid metabolism. Patel's research provides insights into optimizing AMD care through next-generation supplement formulations aimed at reducing disease progression.

Zack Oakey, MD

Specialties: Ophthalmology

Bio: Zack Oakey, MD, authored a Retinal Physician case presentation on toxic maculopathies, focusing on the differential diagnosis and retinal imaging findings associated with pentosan polysulfate sodium retinopathy and other medication-related macular toxicities.

PentaVision

Retinal Physician

The Evolution of AREDS

5 Key Takeaways

1

2

3

4

5

Recommendations